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The analysis of heart rate variability (HRV) has become an increasingly popular and 
important tool for studying many disease pathologies in the past twenty years. HRV 
analyses are methods used to non-invasively quantify variability within heart rate.  
Purposes of this study were to design, evaluate, and apply an easy to use and open-source 
HRV analysis software package (HRVAS). HRVAS implements four major categories of 
HRV techniques: statistical and time-domain analysis, frequency-domain analysis, 
nonlinear analysis, and time-frequency analysis. Software evaluations were accomplished 
by performing HRV analysis on simulated and public congestive heart failure (CHF) 
data. Application of HRVAS included studying the effects of hyperaldosteronism on 
HRV in rats. Simulation and CHF results demonstrated that HRVAS was a dependable 
HRV analysis tool. Results from the rat hyperaldosteronism model showed that 5 of 26 
HRV measures were statistically significant (p<0.05). HRVAS provides a useful tool for 
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1 Introduction  
The analysis of heart rate variability (HRV) has become a standard tool for studying a 
wide variety of clinical and research topics. These areas have ranged from autonomic 
nervous system (ANS) regulation, risk stratification for sudden cardiac death, diabetic 
neuropathy, pharmaceutical evaluations, to psychological disorders  [1-5]. Heart rate 
variability, in its simplest form, is the variation in time between consecutive heart beats. 
HRV analysis attempts to non-invasively quantify these variations which in some 
instances can be markers of pathophysiology.  Heart rate (HR), like many physiological 
set points, e.g., blood pressure and temperature, is not a static parameter, but rather 
changes within a range in reaction to bodily demands.  Healthy cardiovascular systems 
are ready to quickly detect and respond to changing needs placed upon the system in 
order to restore homeostasis and permit directed activities. Conversely, it is often shown 
that invariant HR is linked to disease systems such as heart failure [2, 6]. HRV provides a 
means to assess overall cardiac health and its regulating system. 
1.1 Background 
In 1963 Hon and Lee were among the first to show the clinical significance of HRV 
by noting that changes in interbeat intervals (IBI) preceded both fetal distress and 
changes in overall heart rate [7]. In the late 1960’s and early 1980’s others began to 
describe physiological rhythms contained within the beat-to-beat HR signal [8-10]. A 10-
year study relating short-term IBI differences to autonomic neuropathy was published in 
1985 by Ewing et al. [11]. Wolf et al. contributed substantially to the HRV community in 
1977 by showing an association between higher mortality risks after myocardial 
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infarction and reduced HRV [12]. Again during the 1980’s HRV was established as a 
“strong and independent predictor” for post-infarction mortality [13-15]. The decades of 
1970 and 1980 also produced strong evidence relating reduced HRV to severity of 
diabetic autonomic neuropathy [16, 17]. 
The increasing availability and computational power of personal computers have 
contributed much to the increase in HRV analysis. In 1981, a signal analysis tool for 
quantifying spectral components of a time series was applied to HR fluctuations by 
Akselrod et al [18]. From the 1990’s to present there has been a greater effort to describe 
HRV as a nonlinear signal, and not just combinations of periodic oscillations [19-26]. 
1.2 Physiological Origins of HRV 
In the absence of any outside influences spontaneous and periodic activation of the 
pacemaker cells within the sinoatrial (SA) node determines the intrinsic heart rate. Action 
potentials from the SA node spread throughout the atria to the atrioventricular (AV) node. 
The AV node provides a propagation delay that allows for complete atrial depolarization 
before action potentials propagate through the bundle of His, Purkinje fibers, and 
ultimately throughout the ventricles. 
Modulation of this inherent HR is accomplished by autonomic nervous system 
innervations, the intrinsic cardiac nervous system, reflexes, respiration, and humeral 
inputs. These modulating mechanisms not only act on the SA node but also on the 
atrioventrical (AV) node, myocytes, conduction pathways, and both coronary and 
peripheral vasculature. Correspondingly, cardiac chronotropism (heart rate), inotropism 
(contractility), dromotropism (conduction), and vascular dilation/contraction are adjusted 
to meet the dynamic cardiovascular demands of the body. The ultimate goal of the 
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cardiovascular system is to sustain and associated level of arterial blood pressure to 
ensure sufficient organ perfusion. 
1.2.1 Parasympathetic Nervous System 
Efferent nerve fibers of the parasympathetic nervous system (PNS) originate in 
collections of neurons in the dorsal vagal nucleus and the nucleus ambiguous of the 
medulla. From the medulla PNS neurons descend to cardiac tissues via the tenth cranial 
nerve (vagus) to a series of ganglia in and near the heart. Postsynaptic PNS neurons 
innervate the SA node, AV node, myocytes, conduction pathways, and coronary 
vasculature of the heart. The left vagal nerve primarily innervates the AV node while the 
right vagal nerve innervates the SA node. However, there is some crossover between the 
two. 
Effects of PNS activation on the cardiovascular system are mediated by the 
neurotransmitter acetylcholine. Acetylcholine (ACh) binds to postsynaptic M2 muscarinic 
receptors in both cardiac tissue and vessels. Acetylcholine decreases inotropy, 
chronotropy, and dromotropy in the heart and causes vasodilation in vessels including 
coronary arteries. 
1.2.2 Sympathetic Nervous System 
Efferent sympathetic nervous system (SNS) nerve fibers descend from centers in the 
medulla through the spinal cord and exit at the T1-L2 dorsal roots. Presynaptic neurons 
synapse with postganglionic neurons of paravertebral ganglia. These postganglionic 
neurons innervate the SA node, AV node, conduction system, myocytes, coronary 
vasculature, and other vessels. 
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Sympathetic neurons release the neurotransmitter norepinephrine (NE) which binds to 
postsynaptic β1, β2, and α1 adrenergic receptors on the heart with a higher affinity for β1. 
These receptors increase chronotropy, dromotropy, and inotropy. NE also binds to 
presynaptic α2-adrenoceptors at the heart and acts as a negative feedback loop that 
reduced NE release.  
At vessels, NE binds to postsynaptic α2 and α1-adrenoceptors to produce 
vasoconstriction and binds to β2-adrenoceptors to produce vasodilation. As with cardiac 
tissue, presynaptic binding of NE to α2-adrenoceptors in vessels produces a negative 
feedback reducing NE release. NE also binds to presynaptic β2 receptors, but produces a 
positive feedback of NE release. “Overall effects of sympathetic activation are to increase 
cardiac output, systemic vascular resistance (both arteries and veins), and arterial blood 
pressure” [27]. 
1.2.3 Intrinsic Cardiac Nervous System 
Traditionally the ANS was thought to be the only nervous system directly associated 
with HR modulating capabilities. However, recent evidence has shown that there is an 
intrinsic cardiac network (ICN) capable of mediating intracardiac reflexes. In addition to 
the classically described parasympathetic postganglionic neurons, the ICN includes 
sensor neurons, interneurons, and catecholaminergic neurons [28].  “Thus, neural control 




1.2.4 Reflex Control 
The previous few sections primarily discussed efferent pathways and mechanism for 
modulating HR and other cardiovascular significant events. Cardiovascular control, as 
with most physiological control systems, is not a simple feed-forward control system. 
Autonomic feedback loops or feedback reflexes exist to allow hemodynamic 
homeostasis. Receptor types involved in reflex control can include pressure, stretch, 
chemical, pain, and thermal receptors. 
Reflexes involved in autonomic control of HR are many, e.g., baroreceptor, 
Baingridge, Cushing, pain, diving, and temperature reflex. The most often described 
reflex associated with HR, in context to HRV, is the baroreceptor reflex or baroreflex 
[29-31]. Baroreceptors located in the aortic arch and carotid sinus synapse with neurons 
that project superiorly to the brainstem. The aortic arch is innervated by afferent neurons 
from the aortic nerve which combines with other afferent neurons in the vagus nerve. 
Afferent neurons innervating the carotid sinus receptors connect to the brainstem using 
the glossopharyngeal nerve (cranial nerve IX). Both groups of afferent neurons synapse 
with interneurons of the nucleus tractus solitaries (NTS) within the brainstem and 
modulate the activity of both the PSN and SNS. Excitatory interneurons from the NTS, 
which normally are excited by tonic baroreceptor activity, stimulate vagal activity and 
inhibit sympathetic activity. Connections also exist between the NTS and hypothalamus.  
To illustrate how the baroreflex works, consider the course of events that occur in 
response to a person moving from supine to standing. Gravity simultaneously causes 
blood to pool in the venous system and decreases venous return, which results in lower 
central venous pressure, ventricular preload, and thus decreased arterial blood pressure. 
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Reduced arterial pressure results in less baroreceptor firing. The NTS responds by 
reducing parasympathetic outflow and un-inhibiting (increasing) sympathetic outflow. 
These ANS changes produce increases in chronotropy, inotropy, and vascular resistance. 
The inability of the body to react in this manner would result in syncope (fainting). 
Other types of reflexes incorporate chemical sensitive receptors. These 
chemoreceptors are typically sensitive to partial pressures of O2 (pO2), CO2 (pCO2), and 
to pH. Peripheral chemoreceptors within the carotid and aortic bodies, like the 
baroreceptors, project to the medulla via the sinus (then the glossopharyngeal) nerve and 
the vagus nerve respectively. Peripheral chemoreceptors increase firing in response to 
reduced arterial pO2 (hypoxemia), increased pCO2 (hypercapnia), and increased pH 
(acidosis). Central chemoreceptors located in the medulla regions that control 
cardiovascular and respiratory activity respond similarly, but not directly in response to 
hypoxia.  
1.2.5 Respiratory Sinus Arrhythmia 
Another type of reflex often mentioned in HRV literature is the respiratory sinus 
arrhythmia (RSA) [32]. RSA is a cyclic modulation in the HR correlated with respiration. 
Vagal afferent nerves in the lungs are excited during inhalation due to distention. The 
result is similar to the increased baroreceptor firing of the baroreflex. Increase afferent 
vagal activity during inhalation produces lowered vagal efferent activity and increased 
sympathetic activity, thereby increasing HR. The opposite is true for expiration. 
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1.2.6 Humoral Control 
Lastly there exist means of modulating HR (directly and indirectly) by circulating and 
localized release of humoral substances. Indirect effects on the heart and vessels come 
from changes in blood volume. One set of humoral substances are the circulating 
catecholamines released from the adrenal medulla and sympathetic nerves that innervate 
blood vessels. The adrenal medulla primarily releases epinephrine, and sympathetic 
nerves primarily release norepinephrine. Both of these releases causes increase in HR, 
however, other reflex controls may secondarily lead to a decrease [27]. Natriuretic 
peptides, arginine vasopressin, nitric oxide, neuropeptides Y, and factors related to the 
renin-angiotensin-aldosterone system (see Chapter 5) also contribute to changes in HR 
[27, 33].  
1.2.7 ANS Components of HRV 
HRV studies describe distinct oscillations contained in IBI time series linked to 
autonomic influences of HR [34-38]. With the use of computer analysis and 
pharmacological studies, two primary HR oscillations have been defined. The high 
frequency (HF) oscillation  is often associated with the RSA and has nominal range of 
0.15-0.4 Hz [39]. Because RSA is regarded as being mediated by vagus activity, the HF 
oscillation is often denoted as a measure of vagal activity [40].  The other primary HR 
oscillation described in HRV is the low frequency (LF) oscillation existing between 0.04-
0.15 Hz [39]. This band includes the 10 second rhythm or Mayer wave [41]. Some 
controversy exists on whether only sympathetic activity is represented in the LF 
oscillation, but most consider LF a combination of sympathetic and vagal activity [40].  
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To validate the aforementioned HR oscillations, both electrophysiological and 
pharmacological studies have been performed on the SNS and PNS [34, 35, 37, 42]. 
Selectively blocking or stimulating sympathetic activity, vagal activity, or both provided 
a means to link frequency bands with the ANS branches. Specifically, an antagonist for 
the muscarinic acetylcholine receptors, atropine, was used in vagal blockades, while beta-
adrenergic antagonists such as propranolol were used for sympathetic blockade. 
These studies further revealed that the vagal mediated changes of HR are faster than 
sympathetically mediated changes [40]. The primary reason for differences of response 
rates is attributed to the receptor processes and postsynaptic responses. It was 
demonstrated that the majority of molecules involved in muscarinic binding processes are 
mostly located within the cell membrane [43]. Conversely, adrenergic receptor binding 
processes involve secondary messaging pathways before membrane ion channel changes 
and thus causing a longer response time [43]. 
In addition to LF and HF oscillations, two lesser described HR oscillations exist 
below 0.04 Hz. The very low frequency oscillation (VLF; 0.003-0.05 Hz) and ultra low 
frequency oscillation (ULF; below 0.003 Hz) have been studied less than the preceding 
two bands. Thermoregulatory cycles and fluctuations of plasma renin activity may 
contribute to VLF [44-46]. Circadian rhythms are typically the acknowledged primary 
contributor to the ULF frequency band [40, 44]. These two oscillations, particularly ULF, 
are often contaminated with low frequency trends resulting from possible intrinsic non-
stationarities of IBI signals [47]. 
The above descriptions of physiological mechanisms that affect HR are by no means 
an exhaustive list. Heart rate is controlled by many feed-back and feed-forward systems 
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that are directly and/or indirectly integrated together. The complex interplay of these 
systems leads to variations in HR that are used in HRV analysis.  
1.3 Justification and Purpose of Research 
HRV analysis has become a widespread tool used by researchers and clinicians and 
the interest is continuing to increase. A literature search in the National Library of 
Medicine’s Medline database show that more than 1,000 HRV articles were published in 
2009, over 4,000 in the last 5 years, and a two fold increase in HRV publication per year 
compared to 10 years ago. Interest has increase to the point that commercial HRV 
software is now available for clinicians to aid in cardiovascular disease diagnosis, and for 
continuous monitoring. Disease classification, treatment planning, progress monitoring, 
and outcome predicting are primary goals in health care that generate much interest with 
HRV. 
Though the use of HRV is prevalent, there is a continuing need for software packages 
that include updated and validated HRV analysis methods in an easy to use platform for 
both researchers and clinicians. Because any novel techniques and some current 
techniques can produce obscure results, there is a need for interpretive methods to give 
physiological meaning to HRV analysis particularly for clinicians. Another need in HRV 
analysis is to standardize analysis techniques and to characterize HRV measures for 
specific populations of pathophysiology such as heart failure and models of induced heart 
failure such as hyperaldosteronism. 
The purposes of this study are three fold: (1) Design a HRV analysis software 
package with the intended consequence of developing an understanding of techniques 
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used in HRV analysis, (2) evaluate the software using simulated and public data, and (3) 
apply the software by studying the effects of hyperaldosteronism on HRV in rats. 
1.4 Thesis Guide 
Chapter 2 introduces several techniques used in HRV analysis. Each of these 
techniques was implemented within the Heart Rate Variability Analysis Software 
(HRVAS). Chapter 3 describes specific design elements of HRVAS. Chapter 4 discusses 
two evaluations that were performed to validate HRVAS. Chapter 5 discusses the 
application of HRVAS to study hyperaldosteronism in rats. Finally, Chapter 6 includes an 




2 HRV Analysis 
This chapter describes several analysis methods used in HRV. The first section 
describes techniques used to process IBI time series prior to HRV analysis. The 
remaining four sections describe four major categories of HRV analysis. These four 
major categories include: time based metrics (e.g., variance); frequency based metrics 
that evaluate powers or ratios of powers within certain frequency bands; nonlinear based 
metrics that evaluate complexity and self-similarity; and time-frequency metrics that 
expand on frequency based metrics by monitoring them through time. For alternative 
overviews of HRV analysis see articles by Seely et al. [48], Acharya et al. [49], Berntson 
et al. [40], and Malik et al. [39]. 
2.1 IBI Extraction 
Data series used in HRV analysis are time series containing beat-to-beat intervals 
extracted from ECG signals. Temporal locations of beats are frequently based on the R-
wave because it is often the easiest wave to distinguish. R waves typically have the 
largest amplitudes compared to surrounding P, Q, S, and T waveforms. Thus a beat-to-
beat interval can be defined as the time difference between consecutive R peaks (RR 
interval). Because the R wave is not the only temporal marker for beat locations, e.g., 
QRS complex, some use the term IBI as a generalization to represent any beat-to-beat 
intervals.  Additionally, RR intervals originating from normal sinus rhythms are 
sometimes referred to as NN (normal-to-normal) intervals. Thus, standard nomenclature 
of “NN” is used in place of IBI or RR to indicate IBI’s containing no ectopic intervals. 
Many authors, including this research, interchangeably use IBI, RR, or NN (normal-to-
normal) to represent IBI series assuming ectopic beats have been corrected.   
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Fig. 1 shows a hypothetical ECG and how IBI’s are determined based on R waves. 
IBI(1) and IBI (2) represent the first and second data point of the IBI time series signal. 
The IBI time series of an ECG segment containing N beats is given by 
    1 ( ) :1 1IBI n beat n beat n n N       (2.1) 
where beat(n) is the time location of the nth beat. 
 
 
Fig. 1 – Determination of IBI. Simulated ECG containing three beats with arbitrary units 
of time and amplitude. Time intervals corresponding to the IBI are indicated by IBI(1) 
and IBI(2). ECG morphology is shown by five characteristic waves P, Q, R, S, and T. 
 
2.2 Preprocessing 
Preprocessing of IBI time series data is frequently required before HRV analysis to 
reduce analysis errors. The three primary types of IBI preprocessing are ectopic 
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beat/interval correction, detrending, and IBI resampling. HRV analysis errors due to 
ectopic beats and IBI trends have been reported by Thuraisingham [50] and Colak [51]. 
In the context of IBI, ectopic beats refer to any IBI based on one or more abnormal beats. 
Any abnormal IBI due to a false/missed beat, fiducial point misalignment, or cardiac 
ectopy may be considered ectopic. 
IBI time series also contain slowly varying trends that are generally assumed to be 
inherent to most biological signals including IBI. Some HRV analysis methods assume 
that IBI signals are stationary or absent of low frequency trends. Specifically, power 
spectrum estimations based on Fourier transform require that the random variable of 
interest be wide sense stationary (the mean does not change with time) [52]. To alleviate 
any non-stationarities within IBI time series, detrending is often used before HRV 
analysis [51, 53, 54]. In addition to stationarity, these methods require evenly sampled 
IBI, which is inherently not the case for IBI signals. Fig. 2 illustrates an IBI time series 





Fig. 2 – IBI signal before and after detrending and ectopic interval removal. IBI time 
series from healthy human. 
 
2.2.1 Ectopic Interval Detection 
Before ectopic intervals can be corrected they must first be detected or marked. Here 
three detection techniques are discussed. Although the term filter is used in this section, 
no change to the original IBI occurs during ectopic interval detection. The percentage 
filter locates intervals that change by more than a user defined percentage (often 20%) 
from the previous interval [55]. This method locates any sudden or abrupt IBI changes. 
Another method used to detect ectopic intervals is the standard deviation filter which 
marks outliers as being intervals that lie beyond the overall mean IBI by a user defined 
value of standard deviations (often 3 SD) [55]. Lastly, the median filter acts as an 
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impulse rejection filter with threshold to delineate ectopic intervals [50]. The median 
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2.2.2 Ectopic Interval Correction 
Four correction techniques are described to replace ectopic intervals found during the 
detection process. The first technique is to simply remove any ectopic intervals found. 
Simple ectopic interval removal has been shown to be as effective as other replacement 
methods [56]. Another method replaces any ectopic interval with the mean value of w 
neighboring IBI intervals centered on the ectopic interval using Equation (2.3) . 
Similarly, the median method replaces ectopic intervals with the median value of w 
neighboring IBI intervals centered on the ectopic interval using Equation (2.4) [50]. 
Lastly, cubic spline replacement replaces ectopic intervals using cubic spline 
interpolation. 





ibi n mean ibi n m m
 
   
 
  (2.3) 





ibi n med ibi n m m
 
   
 
 (2.4) 
2.2.3 IBI Detrending 
Several methods of detrending exist in the literature to remove low frequency trends 
including: linear detrending, polynomial detrending, wavelet detrending, wavelet packet 
detrending, and smoothing priors detrending.  
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2.2.3.1 Linear and Polynomial Detrending 
Two of the simplest methods used for detrending IBI series are linear and polynomial 
detrending [57-59]. Linear detrending is accomplished by removing a linear least-
squares-fit from the IBI series. Similarly, polynomial detrending removes a second or 
third order polynomial fit (in a least squares sense) from the IBI series.  
2.2.3.2 Wavelet Detrending  
Wavelet detrending is accomplished by decomposing the original IBI time series into 
a tree of approximation and detail coefficients using discrete wavelet transform (DWT) 
(see Section 2.5.2.2). Each decomposed sub-band is associated with a range of 
frequencies with the highest level of approximation containing the lowest frequencies. 
Removing the low frequency trend can be accomplished by two methods. The first 
method sets all the wavelet coefficients of the highest level approximation (lowest 
frequency) to zero, and then performs an inverse DWT. The alternative method 
reconstructs only the highest approximation sub-band which is then subtracted from the 
original IBI series [50]. Either method effectively applies signal detrending. 
2.2.3.3 Wavelet Packet Detrending 
Detrending using wavelet packets works similar to the detrending method based on 
DWT mentioned in the previous section. Instead of decomposing the signal using DWT 
the discrete wavelet packet transform (DWPT) is used (see Section 2.5.2.2). Wavelet 
coefficients of sub-bands that contain frequency components of any unwanted trend are 
set to zero. Reconstruction of the IBI series using inverse DWPT produces a detrended 
IBI series [60]. As before, an alternative detrending approach using DWPT is to 
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decompose the signal, reconstruct any unwanted components, and subtract the unwanted 
components from the original signal.   
2.2.3.4 Smoothing Priors 
The final detrending method to be discussed is the smoothing priors approach [60, 
61].  In the smoothing priors approach a N-1 long, an equally sampled IBI time series is 
represented as the combination of  stationary and trend components, 
stationary trendz z z  . 
This method computes a stationary signal from the original. The estimated stationary 
component is written as 





stationaryz z z 

    Hθ I I D D  (2.5) 
where 
 1 xN M
H R is the observation matrix. For simplification, an identity matrix is 
used in place of the observation matrix H . ˆ
λθ  
represents the estimate of the regression 
parameters with   as the regularization parameter and 
   3 x 1
2
N N 
D R  is the second 
order difference matrix. 
2.2.4 IBI Resampling 
In addition to most Fourier based power spectrum estimates (see Chapter 2.4) 
requiring signal stationarity; they also require time series that are regularly sampled in 
time. Spectrum estimates taken from irregularly time sampled signals can introduce 
additional harmonics into the power spectrum [62]. For this reason, IBI time series must 
be resampled prior to some power spectrum estimates. Commonly used resampling 
schemes are cubic spline and linear interpolation [63]. 
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2.3 Time-Domain Analysis 
2.3.1 Statistical Measures 
Time domain HRV analyses are often classified as statistical or geometric methods. 
Statistical time-domain measures are statistical based measures calculated directly from 
the IBI series. Time domain measures include: mean IBI, the standard deviation of the 
NN interval series (SDNN), the root mean square of successive differences of the IBI 
series (RMSSD), the number of successive differences that are greater than x 
milliseconds (NNx),  and the percentage of total intervals that successively differ by more 
than x milliseconds (pNNx) [64].  
Two variants of the SDNN are used with longer datasets. The first step in both of 
these variations involves separating the IBI series into non-overlapping segments. For 
human IBI’s the segment lengths are often five minutes [39]. The first variant is the 
SDNN index or SDNNi, Equation (2.6) , and is computed by finding the standard 
deviation of each IBI segment and then returning the mean value of standard deviations. 
The SDANN measure is computed in the opposite manner, Equation (2.7). SDANN 
computes the mean IBI of each segment and then returns the standard deviation of all 
















SDANN meanIBI i meanIBI
M 
   
  (2.7) 
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where SDNN(i) represents the SDNN value of the i
th
 IBI segment, meanIBI(i) represent 
the mean IBI value of the i
th
 IBI segment, and M is the total number of segments. 
2.3.2 Geometric Measures 
Geometric HRV measures are based on calculations taken from a geometric pattern 
who’s basis lies with the IBI series [39]. The most common geometric pattern used is the 
histogram of IBI. Two measures based on the IBI histogram are the HRV triangular index 
(HRVti) and the triangular interpolation of the NN interval histogram (TINN). Fig. 3 
represents the histogram of a hypothetical IBI series where D(t) is the density distribution 
of IBI. The maximum value of D(t) is represented by Y and is located at t=X. HRVti is 
the value obtained by dividing the area integral of D(t) by the maximum value Y. If the 
distribution D(t) is on a discrete horizontal scale then the area integral is just the total 





  (2.8) 
For the computation of TINN the values N and M are established on the time axis and 
a triangular function q(t) constructed such that q(t)=0 for M ≤ t ≤ N.  The peak of the 




( ( ) ( ))D t q t dt

 .  Finally, TINN is expressed in milliseconds 
and computed using [39] 





Fig. 3 – Histogram of hypothetical IBI time series. D(t) represents the sample 
distribution. q(t) represents a triangular function fitted to D(t) by minimizing the integral 
of the squared difference between D(t) and q(t). Y = D(X) = max(D). 
 
2.4  Frequency-Domain Analysis 
Fluctuations in HR are often thought to be periodic and occurring on many time 
scales [65]. Quantifying these fluctuations within the IBI time series can be done by 
calculating the power spectrum density (PSD). The PSD presents spectral power density 
of a time series as a function of frequency. Therefore, PSD estimates can give 
information about the amount of power in which certain frequencies contribute to a time 
series.  
In general, frequency-domain HRV analysis is concerned with four previously 
mentioned frequency oscillations or bands [39]: ULF, VLF, LF, and  HF. For humans 
ULF, VLF, LF, and HF frequency bands are defined to be 0-0.0033 Hz, 0.003-0.04 Hz, 
0.04-0.15 Hz, and 0.15-0.4 Hz respectively. The ULF and VLF are often ignored due to 
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the lack of long data recordings needed to accurately resolve these frequencies or due to 
the use of IBI detrending techniques that may destroy information within those bands.  
Typical HRV measures taken from frequency-domain analysis are powers within 
frequency bands and ratios of powers. The amount of power contained within a frequency 
band is obtained by integrating the PSD between the band frequency limits. Measures of 
spectral power are reported as absolute (aVLF, aLF, aHF), percentage of the sum of aLF 
and aHF (pLF, pHF), or normalized to total power (nLF, nHF). In addition to the power 
measures, the ratio of LF to HF (LFHF) provides a so called sympatho-vagal balance. 
Finally, less commonly mentioned measures are the peak frequencies within the VLF, 
LF, and HF bands. 
Estimating the PSD can be performed using many methods, but methods based on 
Fast-Fourier Transform (FFT) and autoregressive (AR) modeling are perhaps the most 
popular in spectral analysis of HRV [65]. Classical power spectrum estimates developed 
by Bartlett (1948), Blackman and Tukey (1958), and Welch (1967) are examples of 
methods based on FFT [66]. Because the FFT makes no assumptions on how the data are 
generated the classical methods are often referred to as non-parametric. The AR power 
spectrum methods do make assumptions and are therefore called parametric. Contributing 
to the popularity of the FFT based estimates are their simplicity, broad understanding, 
and ease of computation using modern computers and software.  
However, both FFT and AR based PSD estimates have prerequisites that are seldom 
if ever met by biological signals such as cardiac IBI series [67]. Both methods require the 
analyzed time signal to be stationary and evenly sampled, which is inherently not the case 
with IBI signals [52, 66]. The commonly used linear and cubic spline resampling were 
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shown to overestimate the LFHF ratio with an error that is greater than the error between 
population differences [68]. Consequently, other methods such as the Lomb-Scargle 
periodogram and methods based on wavelet transforms are becoming popular [32, 69-
73]. Lomb-Scargle does not require resampling and wavelet transform based estimates do 
not require stationarity [74]. Despite the aforementioned limitations of FFT and AR 
based PSD estimates, they are widely used in HRV. 
2.4.1 Welch Periodogram 
To understand Welch’s periodogram one must first understand the discrete Fourier 
transform (DFT), the basic periodogram, and the modified periodogram. The N-point 















  (2.10) 
Practical computations of the DFT use the FFT for speed advantages. The periodogram, 
extension of the DFT, is a basic method of estimating power spectral density of a time 
series and is given by 
















   (2.11) 
Reducing spectral leakage of the periodogram can be accomplished by incorporating a 
weighted windowing function w(n), e.g., Hamming and Hanning, to the input series. Data 
near the edges of the time series are given less weight compared to data nearer the center. 
Thus, the modified periodogram is given by 



























U M w n


  . Finally, in an effort to reduce the variance of the periodogram 
estimation, the Welch method separates the data series into N overlapping segments.  As 
with the modified periodogram the Welch method applies a weighting window to reduce 
spectral leakage, but weighting is applied to each segment. Finally an averaged PSD is 
calculated using all segments. Power spectral density by the Welch periodogram is given 
by 











   (2.13) 
where  ,M iP f  is the i
th
 modified periodogram from the data series. 
2.4.2 Burg Periodogram 
Autoregressive spectral estimation methods differ from non-parametric methods in 
that they attempt to model the data instead of estimating the PSD directly. Several 
modeling methods exist for AR spectrum estimation, but the Burg method is the most 
common in HRV [49, 75, 76].  
The power spectrum of a p
th
























where εp is the total  least square error, fs is the sample rate, and pa are the Burg AR 
model parameters [77]. Boardman, et al. suggests that a model order of p=16-20 is a 
sound choice for HRV in human IBI resampled at 2-4 Hz [78]. 
24 
 
2.4.3 Lomb-Scargle Periodogram 
As mentioned before the Lomb-Scargle periodogram (LSP) method of estimating 
PSD does not require resampling. The LSP only uses available data. Conceptually LSP 
estimates the frequency spectrum by performing a least squares fit of sinusoids to the 
data. Unlike Welch’s periodogram weighted windowing functions are not applied to data 
in LSP because standard weighting methods cannot be applied to unevenly sampled data. 
The LSP of a non-uniformly sampled, real-valued data sequence X of length N for 
arbitrary times tn is defined by 
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where x  and σ
2
 are the mean and variance of the time series, and 
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     
    
  .  τ is a frequency dependent time delay, 
defined to make the periodogram insensitive to time shift[69-71]. A more detailed 
description of the LSP appears in [70, 79].  Clifford et al. showed that ectopic beat 
removal of up to 20% of the data points in an IBI signal does not introduce a 
“significant” error in frequency-domain HRV measures based on LSP [68]. Because of 
the resistance to errors from data removal and resampling, LSP could be the preferred 
power spectrum estimation method for HRV. Comparison of the Welch, Burg, and 





Fig. 4 – Comparison of PSD estimates. Estimates include (a) Welch periodogram, (b) 
Burg autoregressive periodogram, and (c) Lomb-Scargle periodogram estimates. HRV 
frequency bands are labeled as very low frequency (VLF, 0-0.04 Hz),  low frequency 
(LF, 0.04-0.15 Hz), and high frequency (HF, 0.15-0.4 Hz). PSD’s computed using 
preprocessed IBI from healthy human. Powers represent percent of total power. 
 
2.5 Time-Frequency Analysis 
HRV analysis by means of frequency-domain methods can only yield information 
about how IBI signal power is distributed in the frequency domain. They provide no 
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insight into the temporal evolution of the spectrum. Methods used to allow simultaneous 
viewing of both time and frequency information are often termed time-frequency 
analyses. Like frequency-domain analysis, time-frequency HRV analysis quantifies VLF, 
LF, and HF related measures. The two primary types of time-frequency analysis used are 
the windowed Fourier transform (also called short-time Fourier transform, STFT) and the 
continuous wavelet transform [80].  To include spectral estimation methods other than 
the Fourier transform, the term windowed periodogram will be used in place of 
windowed Fourier transform. This generalization allows the inclusion of the windowed 
Burg periodogram and windowed Lomb-Scargle periodogram. 
2.5.1 Windowed Periodogram 
The windowed power spectrum is an extension of the basic PSD. As the term implies, 
the data is broken down into consecutive (overlapping or not) segments or windows. The 
PSD is then computed for each segment. This is similar to the technique use by Bartlett 
and Welch. However, those methods lose any temporal information by averaging all 
PSD’s into a single PSD. Unlike Welch’s method, the windowed periodogram can use 
other techniques to compute the PSD, e.g. Burg periodogram. Plotting PSD values onto a 
two-dimensional plane with frequency and time as the vertical and horizontal axes 
respectively produces a spectrogram as seen in Fig. 5. 
Two alternatives are the windowed Burg periodogram and the windowed Lomb-
Scargle periodogram [81, 82]. For the windowed Burg periodogram the entire data series 
is first resampled and then broken into segments of equal lengths. Finally, the PSD is 
computed for each segment using the Burg periodogram. 
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The windowed Lomb-Scargle periodogram is computed in almost the same manner. 
First, the data is broken into segments of equal lengths of time [71]. Due to the uneven 
sampling of IBI’s, each segment can contain differing number of data points. Finally, the 





Fig. 5 – Spectrogram and waterfall plot for windowed periodograms. Plots generated 
using preprocessed IBI from healthy human. Plots include (a) Spectrogram using 
windowed Bug periodogram. (b) Spectrogram using windowed LSP (c) Waterfall plot 
containing Burg periodograms of each five minute segment of IBI. 
 
HRV quantification from time-frequency analysis using windowed periodograms can 
be accomplished two ways. The first method computes an averaged or global power 
spectrum and then calculates typical frequency-domain HRV measures, e.g., LF, HF, and 
LFHF. Averaging the power spectrum eliminates any time resolution and defeats some of 
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the purpose of time-frequency analysis, but it provides a way to help control variances by 
averaging many power spectrums [83]. Alternatively, HRV measures can be calculated 
for each segment, and then an average HRV measure computed. The second method 
produces discretely instantaneous frequency-domain measures that are a function of time, 
e.g., LF(t) and LFHF(t). 
From the LFHF instantaneous time series, another index can be extracted called the 
ratio of LFHF ratios (rLFHF) [81].  This measure represents the “global” sympathetic-
parasympathetic equilibrium [81]. Imagine a line drawn through LFHF =1 on the 
instantaneous LFHF plot. Above this line (LFHF >1) there is a sympathetic dominance. 
Below this line (LFHF <1) there is a parasympathetic dominance. The rLFHF ratio is 
obtained by calculating the ratio of the bounded area above the line LFHF=1 to the 
bounded area below. 
2.5.2 Wavelet Transforms 
Wavelet transforms are a relatively recent, but enormously popular tool for analyzing 
and compressing many types of time signals. The term wavelet implies a small wave and 
is of finite length and energy [84]. Like Fourier transform the wavelet transform separates 
a signal into its fundamental components. However, unlike the Fourier transform, wavelet 
transforms can be applied to non-stationary signals and are not limited to a single set of 
basis waveforms for signal decomposition. Fourier transforms rely on the sinusoid 
waveform, whereas wavelet transforms have an infinite set of basis waveforms or mother 
wavelets as long as they satisfy predefined mathematical criteria. This property may 
provide access to information that could be obscured by methods like Fourier analysis 
[85]. Acharya et al. state  that “bio-signals usually exhibit self-similarity patterns in their 
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distribution, and a wavelet which is akin to its fractal shape would yield the best results in 
terms of clarity and distinction of patterns” [85]. 
The following summary of Acharya’s [49] understanding of wavelet transform 
concepts provides an efficient explanation. The wavelet transform correlates a mother 
wavelet with sections of the original signal to produce wavelet coefficients. The mother 
wavelet is shifted/translated in time to generate a set of coefficients along the time signal. 
Next the mother wavelet is contracted or dilated to create coefficients along the time 
series at varying time scales. Here the term scale is analogous to frequency or more 
precisely the pseudo frequency (average frequency). Scaled wavelets are normalized so 
each one contains the same amount of energy. The scale can be thought of as the wavelet 
width and the translation as its location in time. Larger scale values represent smaller 
wavelet size and thus higher frequencies. 
This research is concerned with the continuous wavelet transform (CWT), the discrete 
wavelet transform (DWT), and discrete wavelet packet transform (DWPT). The major 
differences between the three are how the wavelet function is scaled and translated. 
2.5.2.1 Continuous Wavelet Transform 
For a given signal x(t) and wavelet function 
, ( )a b t , the CWT coefficients are given by 
 
1
( , ) ( )
t










  (2.16) 
where ( )t  is the complex conjugate of the mother wavelet ( )t , α is the dilation 
parameter, and τ is the location parameter. The bivariant function W(τ,α) shows the 
similarity of x(t) to a wavelet scaled by α at a given time τ [65]. Theoretically the CWT 
wavelet coefficients are calculated for infinitesimally small translations and scale factors. 
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However, practical implementations of the CWT must balance the number of translations 
and scales to produce acceptable computational times. Most programmatic 
implementations of the CWT allow the user to specify the number of scales to use for 
computation. Plotting CWT coefficients onto a two-dimensional plane with scale and 
location as the vertical and horizontal axes produces a scalogram as seen in Fig. 6.  
 
 
Fig. 6 – CWT scalogram of IBI data. CWT computed using preprocessed IBI from 
healthy human with DOG2 wavelet [86]. The frequency axis is displayed using a log 
scale and represents the equivalent frequency of CWT scales [86]. 
 
2.5.2.2 Discrete Wavelet Transform 
In the case of DWT and DWPT, the scaling and translations are done in a less smooth 
or more discrete manner. Scaling and translating for the DWT are based on powers of 2 




, etc. The dilation function is often represented as a tree of 
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low and high pass filters. The first step of the tree decomposes the original signal into 
detail (high frequency) and approximation (low frequency) components. Detail and 
approximation components for three levels of decomposition are represented in Fig. 7-a 
by A and D. Only the approximations are further split into finer components in the DWT. 
For DWPT both branches of the tree are split into finer components. Fig. 7-b shows the 





















Frequency (fraction of Nyquist)
1.0
W2,2 W2,3
W3,2 W3,3 W3,4 W3,5 W3,6 W3,7











Fig. 7 – DWT decomposition tree. Decomposition trees showing the breakdown of an 
arbitrary original signal into three levels using (a) discrete wavelet transform and (b) 
wavelet packet transform. Horizontal axis shows frequency range as a fraction of the 
Nyquist frequency. DWPT can extract all frequency bands with equal resolution. 
Diagram modified from Tanaka and Hargens [87]. 
  
Quantification of HRV measures from time-frequency analysis by CWT is 
accomplished in a similar manner to that employed for the windowed periodogram. 
Similar in that both can use either the instantaneous or global power spectrums [88].  To 
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obtain HRV measures using instantaneous power methods, the squared modulus of the 
wavelet coefficients is integrated over the desired frequency band [f1 f2]. To integrate 
over a frequency band wavelet scales must be changed to frequencies. The time-scale 
map (scalogram) must be interpreted in terms of a time-frequency map (spectrogram). 
The instantaneous power of the frequency band [f1 f2] is given by  




















    (2.17) 
The wavelet equivalent to an averaged periodogram is the global wavelet spectrum and is 
given by 











   (2.18) 
2.6 Nonlinear Analysis 
On the basis that HR control may contain nonlinear components, there is an 
increasing interest to study HRV using methods other than the standard linear methods, 
i.e., time-domain and spectral analysis. These methods are often included under the 
umbrella term nonlinear HRV analysis. It has been shown that loss of IBI signal 
complexity [50, 89] and loss of fractal like scaling behaviors [90, 91] may be a general 
feature of cardiac pathology. Poincaré plot analysis, entropy based measures, and fractal 
based measures are but a few HRV analysis techniques used. 
2.6.1 Poincaré Plot 
The Poincaré plot or first-return map, named after Henry Poincaré, is a plot of IBI 
intervals versus the previous IBI interval. Poincare plots are a type of nonlinear analysis 
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used to quantify self-similarity [92]. HRV measures based on Poincaré plots are based on 
the idea that each IBI is influenced by the previous one [22]. Thus, pairs of successive 
IBI form an attractor in the Poincare’ plot. Often an ellipse is fitted to the plotted data 
with the long axis along the line of identity defined by y x . Fig. 8 illustrates the 
Poincare’ plot generated using healthy human IBI data. If the center or attractor of the 
ellipse is located at the mean IBI ( IBI ), then 2y x IBI    defines the line 
perpendicular to the line of identify and passing through the mean [93]. Points above the 
line of identity indicate a longer IBI than the preceding IBI, and points below the line of 
identity indicate a shorter IBI than the preceding. Standard deviations along the line of 
identity (SD2) and perpendicular to the line of identity (SD1) represent the magnitude of 
the major and minor axes of the ellipse respectively. SD1 represents the SD of the 
instantaneous beat-to-beat variability or short term variability. SD2 represents the SD of 
the continuous or long-term variability [92, 94]. In reality the ellipse is primarily a visual 
aid and the numerical values of the standard deviations SD1 and SD2 contain the 
important data. Also, the ratio of SD1 to SD2 has been suggested to be strongly 





Fig. 8 – Poincare' Plot using healthy human IBI data. 
 
2.6.2 Sample Entropy 
Sample entropy (SampEn) is an embedded entropy that attempts to quantify a signal’s 
complexity or rate of new information generation [97].   To understand how sample 
entropy is calculated a few definitions follow. Let Xi={x1,…, xi,…xN} represent the 
original N-long IBI series. Let um+1[i]={xi,xi+1,…,xi+m} and um[i]= {xi,xi+1,…,xi+m-1} 
represent m+1 and m length vectors/sequences taken from X. Also, let the distance d be 
the maximum absolute distance between the components of two vectors and is given by 
   [ ], [ ] max [ ] [ ] : 0 1d i j i k j k k m      u u u u .  
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For each i  ≤  N-m a template vector um[i] is compared to all other m length vectors 
um[j] where i ≠ j and j ≤ N-m. The number of j that satisfy d(u[i],u[j]) ≤ r is set as 
m
in . 
The unconditional probability of randomly selecting two m length sequences from a 
signal that have a distance less than r using the relative frequency methods is 
/ ( )m mi iC n N m  . Furthermore the averaged probability is given by 

















 , and 
1m  are calculated for vector lengths of m+1. Finally 
sample entropy is determined by 
      1, , ln /m mSampEn m r N r r       (2.20) 
Fundamentally, SampEn can be described as the negative logarithm of the conditional 
probability of randomly selecting two m-length sequences, from a signal, that have a 
distance less than r between them given that they also have a distance less than r if their 
lengths are increased to m+1. If SampEn is zero, then consecutive sequences are 
identical. Larger values of SampEn represent higher complexity. 
2.6.3 Detrended Fluctuation Analysis 
Fractal scaling or self-similarity are concepts based on the idea that a system or shape 
can be fragmented into smaller parts where each part resembles one another but on 
different scales [48]. The Sierpenski triangle is classic example of fractal geometry. A 
few examples of fractals occurring in nature include snowflakes, shorelines, crystals, and 
some ferns. For the case of IBI, the scale is time. Detrended fluctuation analysis (DFA) 
[98] tries to quantify the fractal like or self-similar properties of non-stationary time 
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series [99, 100]. “This technique is a modification of root-mean-square analysis of 
random walks applied to non-stationary signals” [101].  The root-mean-square fluctuation 
of an integrated and detrended time series is measured at different scales and plotted 
against the size of the scale onto a log-log plot (see Fig. 9).  
First consider an IBI time series of length N. The IBI series is integrated using  




y k IBI i IBI

  
   (2.21) 
where y(k) is the k
th
 value of the integrated series, IBI(i) is the i
th
 interbeat interval, and 
IBI is the average interbeat interval for the entire time series. The integrated time series 
is then separated into segments of length n. A least squares line is fit to the data in each 
segment to define the local trend denoted by yn(k). Next, the integrated time series is 
detrended by subtracting the local trend, yn(k) from each segment. Finally, the root-mean-
squared fluctuation of the integrated and detrended time series is calculated by 
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  (2.22) 
where m represents the window or scale size. F(m) is computed on a user defined range 
of time scales. The linear relationship between log(F) and log(n) represents the scaling 
exponent, α, of the interbeat interval time series. Often two distinct linear regions on the 
log-log plot are used to describe the short term scaling, α1, and the long term scaling, 
α2[100]. These two regions are separated by a breakpoint located around 12-16 beats 





Fig. 9 – Detrended fluctuation analysis using healthy human data. Short term scaling 
exponent and long term scaling exponents are represented by α1 and α2. The breakpoint 





3 Software Design 
3.1 Introduction 
HRV software packages exist in the form of commercial (HRVLive [102] ), 
publically available without source code (Kubios [62]), and open source such as ECGLab 
[81, 103], KARDIA[104], and the PhysioToolkit [105] . All these HRV programs offer 
useful tools for HRV analysis, but they also have disadvantages. The obvious 
disadvantages of commercial packages are the cost, lack of user customization, and 
possibly proprietary algorithms, but the advantage is often an active technical support 
staff and refined product. Additionally, commercial software typically does not offer 
recent or more advanced analysis methods that researchers may want to evaluate. 
Software packages that are available to the public without available source code cannot 
be customized and often have limited or no technical support. Finally, open source code 
packages give the user complete customization, but are often not as refined and easy to 
use as commercial software. Many require the knowledge of alternative operating 
systems such as Linux, and lower level programming languages. Neither of these 
knowledge sets is prevalent with clinicians. 
The analysis software HRVAS was developed using MATLAB version 2008b 
(Mathworks, Natick, MA). HRVAS contains all needed analysis options and results in a 
single graphical user interface (GUI). HRVAS also includes batch processing, a feature 
not available in other HRV software packages. HRVAS is open source and un-compiled. 
Open source code allows for user updates and customization. Analysis results are 
displayed in a tab group to allow for future additional analysis modules and to aid in 
keeping all components within a single GUI.  
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3.2 Graphical User Interface  
The graphical user interface (GUI) consists of three primary components (see Fig. 
10). The upper most plot shows the IBI intervals, trend line, and any ectopic intervals. 
Double clicking this graph will show both the unprocessed and preprocessed IBI. The 
lower left grey area contains all analysis options available to the user. All analysis 
options can be saved and reloaded to allow for quick selection of frequently used options. 
Any options present in the GUI on exit are saved and reloaded the next time HRVAS is 
opened. 
 The lower right section of Fig. 10 contains analysis results. Each set of results 
associated with time-domain, frequency-domain, time-frequency, Poincaré, and nonlinear 
analysis are contained in a labeled tab (see Appendix A). The use of tabs allows for 
future HRV analysis additions. Double clicking on any of plot will redraw it onto a 
separate figure for custom editing and exporting for documents or presentations. 
The frequency-domain analysis tab allows for plotting of Welch periodogram, Burg 
periodogram, and Lomb-Scargle periodogram. The time-frequency tab allows for 
displaying of spectrogram, surface plot, waterfall plot, global power spectrum and 
instaneous LF, HF, and LFHF powers. Time-frequency plots can be drawn using 
windowed Burg periodogram, windowed LSP, or CWT.  
Input data types used by HRVAS are .ibi and .txt files. The expected format of input 
files is an ASCII file with one or two columns of data. Two column files must include IBI 
time stamps (seconds) in the first column and IBI values (seconds) in the second column. 
Files containing only one data column must include only IBI values. Exported analysis 
results are saved to a Microsoft Excel® file. 
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In an effort to reduce the total files needed for using HRVAS, each major HRV 
analysis type, e.g., time-domain, uses only one MATLAB m-file. Similarly, the GUI is 
generated using only one MATLAB m-file. 
 
 
Fig. 10 – HRVAS graphical user interface. The upper most plot is of the IBI intervals and 
trend line. The lower left gray area contains all analysis options. The lower right section 
contains analyses results. 
 
3.3 HRV Analysis in HRVAS 
Fig. 11 represents the analysis process used by HRVAS to compute HRV measures. 
The order of preprocessing in HRVAS is ectopic interval detection, ectopic interval 
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replacement, and IBI detrending. HRV analysis details were discussed in the previous 
chapter. 
A batch processing feature allows for unattended analysis of many IBI or RR interval 
files. For batch processing all files must be contained within a single directory. At 




































The design of HRVAS provides an easy to use interface in which to compute and 
display HRV analysis. Future considerations for improvements include moving all 
analysis options to individual tabs, simplifying the export function, and allowing the user 
to select which HRV analyses are computed. Not having to perform all HRV analyses 
will save processing time and resources. HRVAS will be made available to the public at 
http://hrvas.sourceforge.net/ and at the project’s homepage 
https://sourceforge.net/projects/hrvas/. HRVAS is distributed free of charge under the 
terms of GNU public license so that other users can modify the code and adjust the 




4 Software Evaluation 
4.1 Introduction 
This chapter presents two evaluations that help validate analysis results obtained from 
HRVAS. The first evaluation consisted of computing time-domain, frequency-domain 
and time-frequency HRV measures based on computer simulated ECG signals. The 
second evaluation involved computing all HRV measures using public data from healthy 
and congestive heart failure human subjects in an effort to distinguish between groups 
and compare to previous work. More specifically, the hypothesis was that CHF causes 
reduction in HRV. 
4.2 Simulated Data 
4.2.1 Methods 
4.2.1.1 Data 
Computer simulated ECG with IBI were generated to evaluate the reliability of some 
HRV measures obtained from HRVAS. The simulation algorithm was implemented in 
MATLAB using the ECGSYN model [106]. ECGSYN generates both ECG signals and 
locations of all P, Q, R, S, and T waves. R wave locations were used to generate IBI time 
series. Three hundred, 30-minute synthetic ECG segments and three hundred, five-minute 
synthetic ECG segments were generated with sample rates of 256 Hz. Each segment had 
a mean HR of 60 bpm (beats/min) and standard deviation of 1 bpm. The ECG generated 
contained oscillations centered at 0.1 and 0.25 Hz to represent the center frequency of 
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hypothetical LF and HF contributions respectively. Furthermore, the ratio of LF to HF 
power was specified to be 1.0. 
4.2.1.2 HRV Analysis 
Time-domain, frequency-domain, and time-frequency HRV measures were computed 
using HRVAS for comparison with parameters used in generating the synthetic ECG. 
Mean IBI, SDNN, mean HR, and SDHR were computed for time-domain HRV measures. 
Peak LF, peak HF, nLF,  nHF, and LFHF ratios were computed using Welch, Burg, and 
Lomb-Scargle periodograms. Peak LF, peak HF, nLF, nHF, and LFHF ratios were also 
computed in a time-frequency manner using windowed Burg periodogram, windowed 
LSP, and CWT for the 30-minute segments only. Analysis options included: IBI resample 
rate (4 Hz), Welch window width (1024 pts.), Welch window overlap (512 pts.), Burg 
model order (16), TF window width (300 s), and TF window overlap (150 s). Frequency 
bands were specified as 0.04-0.15 Hz for LF and 0.15-0.4 Hz for HF. 
Statistical evaluations were performed by inspecting 90% confidence intervals for 
both time and frequency-domain measures. LFHF rations were further considered by 
performing equivalence test [107]. A confidence interval of indifference was determined 
using empirical data from the CARLA study [108]. Confidence intervals of LFHF mean 
differences which remain within the interval of indifference are considered to be 
indifferent from the expected LHFH value of 1.0.  
4.2.2 Results 
HRV analysis using HRVAS produced values that closely corresponded with 
parameters used for synthetic ECG generation. Results are presented as mean with 90% 
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confidence interval (CI). Time-domain HRV values computed for the 5-minute 
simulations included: mean IBI, 999.7 (999.7-999.7) ms; SDNN, 16.7 (16.6-16.8) ms; 
mean HR, 60.0 (60.0-60.0) bpm; SDHR, 1.0 (1.0 -1.0) bpm. Time-domain HRV values 
computed for the 30-minute simulations included: mean IBI, 999.6 (999.6-999.6) ms; 
SDNN, 16.6 (16.6-16.6) ms; mean HR, 60.0 (60.0-60.0) bpm; SDHR, 1.0 (1.0-1.0) bpm. 
Peak LF and peak HF were 0.10 (0.10-0.10) Hz and 0.25 (0.25-0.25) Hz respectively 
for all spectral HRV methods and data lengths. Fig. 12 shows the LF and HF peaks 
present in the Lomb-Scargle spectrogram and global power spectrum of a representative 
synthetic IBI time series.  
 
 
Fig. 12 – Lomb-Scargle spectrogram and global PSD for simulated IBI (LFHF=0.5) 
 
Results for nLF and nHF are summarized in Table 1. Results for LFHF ratios are 
summarized in Table 2. For 5-minute simulations, the Burg periodogram (0.10-0.26) 
produced the most deviation from the expected value of 1.0 and extended beyond the 
interval of indifference of -0.2 to 0.2. LSP produced the most accurate LFHF value (0.02-
0.10). For 30-minute simulations, the Burg periodogram (-0.10 to -0.08) produced the 
49 
 
largest mean difference while the Welch (0.05-0.06) and LS (0.03-0.08) periodograms 
produced the least mean difference from expected. All three methods had mean 
differences within the interval of indifference determined by equivalence test seen in Fig. 
13. Time-Frequency based measures of LFHF for 30-minute simulations showed that the 
windowed Burg periodogram (0.02-0.05) produced the largest mean difference from the 
expected simulated data. The windowed LSP (0.01-0.04) and CWT (0.02-0.03) produced 
LFHF mean differences slightly lower than the windowed Burg method. All three time-
frequency methods produced LFHF mean differences within the interval of indifference. 
 
Table 1 – nLF and nHF results of simulated IBI 
Duration PSD Estimate nLF (%) nHF (%) 
  Mean (90% CI) Mean (90% CI) 
5 min. Welch 0.51 (0.49-.52) 0.49 (0.48-0.51) 
 Burg 0.50 (0.49-0.51) 0.50 (0.49-0.51) 
 LS 0.50 (0.49-0.50) 0.50 (0.50-0.51) 
30 min. Welch 0.51 (0.51-0.51) 0.49 (0.49-0.49) 
 Burg 0.47 (0.46-0.47) 0.53 (0.53-0.54) 
 LS 0.51 (0.50-0.51) 0.49 (0.49-0.50) 
 Win. Burg 0.51 (0.50-0.51) 0.49 (0.49-0.50) 
 Win. LS 0.50 (0.50-0.51) 0.50 (0.49-0.50) 





Table 2 –LFHF results of simulated IBI 
Duration PSD Estimate LFHF (90% CI) Mean Diff (90% CI) 
5 min. Welch 1.13 (1.08-1.18) 0.13 (0.08-0.18) 
 Burg 1.18 (1.10-1.26) 0.18 (0.10-0.26) 
 LS 1.06 (1.02-1.10) 0.06 (0.02-0.10) 
30 min. Welch 1.06 (1.05-1.06) 0.06 (0.05-0.06) 
 Burg 0.90 (0.89-0.92) -0.10 (-0.11 - -0.08) 
 LS 1.05 (1.03-1.08) 0.05 (0.03-0.08) 
 Win. Burg 1.04 (1.02-1.05) 0.04 (0.02-0.05) 
 Win. LS 1.03 (1.01-1.04) 0.03 (0.01-0.04) 
 CWT 1.03 (1.02-1.03) 0.03 (0.02-0.03) 






Fig. 13 – LFHF equivalence test. Values are displayed as mean difference with error bars 
representing the 90% confidence interval. The grayed area represents the confidence 
interval of indifference and is bound by -0.2 to 0.2. 
 
4.2.3 Discussion 
Time-domain HRV analysis results for both 5-minute and 30-minute simulations 
were indifferent compared to the expected parameters used for simulation. Spectral HRV 
measures produced LFHF ratios within the interval of indifference except for the 5-
minute Burg periodogram. Due to a lower nLF and higher nHF powers, the windowed 
Burg periodogram produced a mean LFHF ratio of less than 1.0. The Burg model order 
could have played a role in this deviation from expected LFHF ratio. 
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4.3 Congestive Heart Failure 
5.8 million Americans are living with heart failure with 670,000 new cases and 
56,600 deaths annually [109]. Heart failure is a condition in which the heart has a 
decreased ability to fill and pump blood to the tissues of the body. In congestive heart 
failure (CHF), this decrease causes a backup or congestion of blood in the returning 
vessels. Heart failure can result from pathologies such as coronary artery disease, 
myocardial infarction, high blood pressure, and cardiomyopathy [110]. As a result of 
heart failure, marked changes in autonomic function appear including high sympathetic 
activity and reduced vagal-cardiac activity [28]. Studies have shown that HRV associated 
with heart failure is reduced compared to healthy [6, 111-113].  
4.3.1 Methods 
4.3.1.1 Data 
To evaluate the viability of HRVAS on real data, HRV analysis was performed on 
two public, human datasets taken from the MIT/BIH RR interval database of 
physiological signals hosted at Physionet [105]. The MIT/BIH database included beat 
annotations of long-term (~24h) ECG recordings that were digitized at 128 samples per 
second. Beat annotations, provided in the database, were obtained by automated analysis 
with manual review and correction. The healthy/control group (NSR) originally included 
54 subjects (30 men, 24 women) aged 24-76 years and having normal sinus rhythm. Two 
subjects were excluded due to large numbers of ectopic beats (greater than 2% of total). 
The CHF group originally included 29 subjects (8 men, 21 women) aged 34-79 years and 
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having congestive heart failure (NYHA classes I, II, or III). Ten subjects were excluded 
due to ectopic beat counts exceeding 2% of the total IBI count. 
4.3.1.2 HRV Analysis 
Physionet annotation files were batch converted to IBI files using a custom shell 
script program combined with Physionet’s ann2rr function[105]. HRV analyses were 
performed using HRVAS’s batch processing feature. The computer system used for this 
project did not provide enough RAM for detrending and HRV analysis of these datasets. 
Therefore all HRV analyses were implemented on the High Performance Computing 
(HPC) system at the University of Memphis using 4 GB of memory on a single server 
node.  
IBI preprocessing included ectopic interval detection, ectopic interval removal, and 
detrending. Ectopic interval detection was performed using the percent filter (20%) and 
standard deviation filter (3 SD). Detrending was accomplished using the wavelet packet 
detrending technique with a cutoff frequency of 0.0391 Hz [60]. Frequency bands for 
VLF, LF, and HF were 0-0.04 Hz, 0.04-0.15 Hz, and 0.15-0.4 Hz respectively[39]. Only, 
LSP based Frequency-domain and time-frequency measures were computed. A complete 




Table 3 – HRVAS Analysis Options for NSR/CHF Datasets 
Analysis Parameter (value) or Method 
Ectopic Detection Std. Dev. Filter (3 SD), Percent Filter (20%) 
Ectopic Correction Remove Ectopic 
Detrending Wavelet Packet (cutoff frequency - 0.039 Hz) 
Time-Domain pNNx (50 ms), SDANN (5 min), HRVti and TINN (32 bin 
histogram) 
Freq.-Domain VLF (0-0.04 Hz), LF (0.04-0.15 Hz), HF (0.15-0.4 Hz), 
Interpolation Rate (2 Hz), Points in PSD (512 pts) 
Nonlinear SampEn (r=0.2 std, m=2), DFA (n=4 to 64 beats, Break Point 
=11 beats) 
Time-Freq. Window (300 s), Overlap (150 s) 
 
4.3.1.3 Statistical Analysis 
Statistical analyses were performed using SPSS v16 (SPSS, Chicago, IL). Each HRV 
statistic was checked for normality by visually inspecting both the histograms and the Q-
Q plots and by considering the Shapiro-Wilk normality test (α=0.05). If both groups 
passed the normality test for a given HRV measure, a two-sample, two-tailed t-test 
(α=0.05) was used to determine between group significance. Levene’s test (α=0.05) for 
equality of variances was used to determine whether to assume equal or unequal 
variances. If either group failed normality test, group significance was determined by the 
non-parametric Mann-Whitney U test (α=0.05). Some HRV measures were able to be 
transformed into normal distributions using a log transform, but this had no effect on 
statistical outcomes of any HRV measure. Therefore, only p values using non-parametric 




All HRV measures showed a significant difference (p<0.05) between healthy and 
CHF subjects except the following: RMSSD, TINN, aTotal, aHF (time-freq.), SD1, and 
DFA-α1. Table 4 summarizes the HRV analysis results. Statistics are presented as mean ± 
standard deviation for NSR vs. CHF respectively.  
All significant time-domain measures were lower for CHF compared to NSR and 
included: mean IBI (783.33±78.41 vs. 685.44±84.98 ms), SDNN (29.22±9.36 vs. 
21.09±11.53 ms), pNN50 (5.53±5.24 vs. 2.92±2.26 %), SDANN (26.36±8.28 vs. 
16.69±7.91 ms), and HRVti (3.07±1.01 vs. 1.80±0.72).   
For frequency-domain measures both nLF power (0.73±0.12 vs. 0.6±0.17 ms
2
) and 
LFHF ratio (3.57±2.12 vs. 2.1±1.74) were reduced in CHF. Conversely, aHF power 
(0.007±0.006 vs. 0.012±0.009 ms
2
) and nHF power (0.27±0.12 vs. 0.4±0.17 n.u.) were 
significantly higher in CHF. All but one significant time-frequency measure were lower 
in CHF compared to NSR and included: aLF power (313.67±211.85 vs. 164.74±207.08 
ms
2
), aTotal power (432.77±277.65 vs. 277.94±333.06 ms
2
), nLF power (60.84±149.55 
vs. 3.04±3.58 %). The nHF power (0.26±0.1 vs. 0.41±0.12 n.u.) obtained by time-
frequency analysis was higher in CHF compared to NSR. 
Nonlinear HRV analysis showed lower values in CHF obtained by Poincare long-
term measure SD2 (194.13±38.99 vs. 95.96±48.14 ms), SampEn (0.78±0.53 vs. 
0.53±0.17), and α1 of the DFA plot (1.28±0.18 vs. 0.89±0.24).  
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Table 4 – HRV Analysis Results for NSR/CHF Datasets 
Measure (units) Sig. Mean ± SD Mean ± SD
MeanIBI (ms) *** 783.33 ± 78.41 685.44 ± 84.98
SDNN (ms) *** 29.22 ± 9.36 21.09 ± 11.53
pNN50 (%) * 5.53 ± 5.24 2.92 ± 2.66
RMSSD (ms) ns 25.70 ± 9.15 23.27 ± 11.31
SDANN (ms) *** 26.36 ± 8.28 16.69 ± 7.91
HRVti *** 3.07 ± 1.01 1.80 ± 0.72
TINN (ms) ns 82.93 ± 38.43 90.51 ± 62.78
aLF (ms
2
) ns 0.02 ± 0.01 0.01 ± 0.01
aHF (ms
2
) * 0.007 ± 0.006 0.012 ± 0.009
aTotal (ms
2
) ns 0.02 ± 0.01 0.03 ± 0.01
nLF (n.u.) *** 0.73 ± 0.12 0.60 ± 0.17
nHF (n.u.) *** 0.27 ± 0.12 0.40 ± 0.17
LFHF (%) *** 3.57 ± 2.12 2.10 ± 1.74
aLF (ms
2
) *** 313.67 ± 211.85 164.74 ± 207.08
aHF (ms
2
) ns 104.67 ± 85.43 81.93 ± 78.76
aTotal (ms
2
) ** 432.77 ± 277.65 277.94 ± 333.06
nLF (n.u.) *** 0.74 ± 0.10 0.59 ± 0.12
nHF (n.u.) *** 0.26 ± 0.10 0.41 ± 0.12
LFHF (%) *** 3.57 ± 1.95 1.67 ± 0.82
rLFHF (%) *** 60.84 ± 149.55 3.04 ± 3.58
SD1 (ms) ns 20.07 ± 12.17 17.92 ± 9.11
SD2 (ms) *** 194.13 ± 38.99 95.96 ± 48.14
SampEn *** 0.78 ± 0.30 0.53 ± 0.17
DFA-α1 *** 1.28 ± 0.18 0.89 ± 0.24
DFA-α2 ns 1.08 ± 0.11 1.16 ± 0.18











HRV analysis results based on time-domain and nonlinear methods followed previous 
findings and expectations. As expected, the results of time-domain analysis show an 
increase in HR and reduction of HRV in CHF compared to NSR. SD2 from the Poincare’ 
plot suggest a reduction in long-term variability in the CHF dataset. Similarly, the lower 
SampEn values in CHF data suggest lower IBI signal complexity. Values of DFA-α1 
obtained for NSR and CHF datasets were similar to values reported by others using these 
or similar data [50, 90, 100, 114]. Ho et al. describes the observed group differences in 
DFA as a “breakdown of fractal scaling properties”  in CHF [114].  
Based on the aforementioned reports that CHF produces lower vagal activity and 
higher sympathetic activity, one would expect HF powers to be lower and LF powers to 
be higher in CHF compared to healthy. However, several studies [114-117] have showed 
seemingly contradictory results using spectral based measures as did this research. 
Guzzetti et al. (2001) [118] suggest that these observed contradictions can be explained 
by the following pathophysiological mechanisms reported in heart failure: 
 central autonomic regulatory impairment [119] 
 decreased responsiveness of sympathetic modulation [120] 
 lower HRV consequent to the stretch of SA node [121] 
 increased chemoreceptor sensitivity [122]. 
Finally, although most of the HRV measures show significant difference between 
groups, many have substantially overlapping distributions. Thus, any single observation 




Although, the HRV analysis results comparing NSR and CHF groups presented in 
this chapter were not all as expected, the results did accomplish the intended chapter 
purposes. These results were in accordance with other studies involving heart failure and 
thus provide an encouraging software evaluation. HRV analyses of synthetic data with 
user specified parameters were able to extract accurate representations of defined 
simulation parameters. Evaluation of HRVAS using both computer-simulated data and 




5 Software Application: HRV in Hyperaldosteronism 
5.1 Introduction 
The adrenal hormone aldosterone has a well-known and important role in regulating 
the sodium-potassium balance of the body via renal mechanisms. However, in the past 
10-15 years  evidence shows that aldosterone also produces non-renal effects particularly 
in the cardiovascular system [123]. This newer evidence has helped explain the link of 
excess aldosterone (hyperaldosteronism) to maladaptive cardiac remodeling [124, 125]. 
Cardiovascular diseases such as hypertension, heart failure, and myocardial infarction are 
marked with increases of aldosterone levels [123]. Specific aldosterone related changes in 
the cardiovascular system include vascular endothelial dysfunction [126], myocardial 
fibrosis [126], myocardial apoptosis [127], cardiac hypertrophy [124], and prolonged 
ventricular action potentials [124]. Blocking aldosterone using aldosterone antagonist 
,e.g.,  spironolactone and eplerenone, can reduce or halt maladaptive cardiac changes in 
animal models [128] and humans [127-129].  Two large trials have further shown that 
treatment with aldosterone antagonist reduces mortality and hospitalization in heart 
failure patients [130, 131]. 
Chapter 4 presented evidence that CHF causes changes in HRV, and the previous 
paragraph established a connection between hyperaldosteronism and HF. From this 
evidence one could hypothesize that a hyperaldosteronism model of HF may produce 
changes in HRV similar to CHF. Therefore, we present the following hypotheses based 
on an 8-week hyperaldosteronism study: 
1. Hyperaldosteronism reduces HRV (treatment effect) 
2. Prolonged hyperaldosteronism further reduces HRV (time effect) 
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One control and one treated dataset, each consisting of 5 male, Sprague-Dawley rats 
(Harlan, Indianapolis, IN), were used. The original data collection came from an 
unpublished study [132]. Rats were purchased at 3-6 weeks old (100-225 g). Treatment 
began when rats were eight weeks old. The hyperaldosteronism treatment group 
(ALDOST) included uninephrectomy (left kidney removed), 6 weeks of subcutaneous 
aldosterone administration (Fisher Scientific International Inc., Hampton, NH) through 
implanted osmotic pumps (Alzet Model 2006, Durect Corporation, Cupertino, CA), and a 
salt diet (drinking water containing 1% NaCl and 0.4% KCl).  Aldosterone was delivered 
continuously at the rate of 0.75 µg/hr.  Radio-transmitters (PhysioTel® model CAf40, 
Data Sciences International, St. Paul, MN) were implanted in all subjects one week prior 
to treatment initiation in order to obtain baseline ECG data. The control group received 
only wireless radio-transmitters. ECG was recorded continuously for eight weeks at a 
sample rate of 1000 Hz using the Dataquest A.R.T. version 4.0 (Data Sciences 
International, St Paul, MN) acquisition system installed on a desktop PC. Seven hours of 
ECG data per subject per week were exported from Dataquest A.R.T. to ASCII files. 




5.2.2 ECG Filtering 
ECG filtering was necessary to maximize beat detection efficiency. High-pass 
filtering was used to remove baseline wander, and was accomplished by subtracting a low 
frequency trend line from the ECG. This trend line was produced by applying a triangular 
(two-pass) moving average filter with a window size of 750 points or (0.75 s, cutoff 
frequency ~ 0.6 Hz) to the ECG signal. Low-pass filtering to remove high frequency 
noise was accomplished using a triangular moving average filter with a window size of 3 
points or (0.003 s, cutoff frequency ~ 155 Hz). Moving average filters provided a simple, 
effective, and fast method to filter ECG. Combining the two techniques effectively 
applied a 0.6-155 Hz bandpass filter to the ECG. The window sizes were primarily 
determined via visual inspections and testing with template matching. Frequency cutoffs 
were determined by frequency response to unit impulse functions. 
5.2.3 ECG Segmentation 
ECG segments for HRV analysis were 10 minutes in duration. One segment from 
each week of treatment (10 weeks) was extracted to provide longitudinal effects of 
aldosterone on HRV. Segments were selected from the middle seven hours occurring 
during the rats 12 hour sleep or lights-on cycle. Segments were extracted from the same 
day each week.  
The process for selecting the 10-minute segment is as follows. A 10 minute moving 
window (overlap of 9 minutes) was passed over the entire seven hours of ECG data. ECG 
statistics were collected for each window. A list of usable ECG segments was constructed 
based on the statistics. Criteria for choosing a usable 10 minute segment included: mean 
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HR above 250 beats/min, total number of ectopic beats less than 1% of total beats, 
absence of significant missing data, and visual inspection of noise and ectopy. Significant 
missing data was defined as having more than 150 consecutive missing data values or 
missing more than 150ms consecutively. Segments with less than 150 consecutive 
missing data values were interpolated using cubic spline. Finally the usable 10 minute 
segment with the lowest HR was chosen for analysis. 
5.2.4 QRS Detection 
QRS complexes were located using a correlation based template matching algorithm. 
Two types of QRS templates were used for template matching. QRS templates were 
created by averaging more than 20 QRS complexes. The first type of template was a 
global template; global in the sense that one template was suitable for all subjects. Eight 
templates were created for each subject (one for each week of treatment) and compared to 
each other by computing a correlation coefficient. The template with largest cumulative 
correlation was selected for use as the global template. In general, approximately 95% of 
cases, the global template was used for template matching. The second type of template 
was a self-template. When global templates failed to yield satisfactory results for a 
particular week of data and resulted in large numbers of missed QRS complexes, a self-
template was generated based on the current ECG data. Both types of templates were 161 
samples in length to encompass the entire rat PQRST cardiac cycle. 
A sliding window was passed across the ECG signal, and a correlation coefficient 
was computed between the template and the ECG contained within each window of equal 
length. This process produced a new data series containing correlation coefficients rxy. 
63 
 
The correlation coefficient between two N length segments of ECG x and y was 
computed using the following equation: 
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Computational speed of template matching was improved using three methods. The 
first method involved reducing the number of times the sliding window translated across 
the signal. By translating every third ECG sample instead of indexing one sample, 1/3 as 
many correlation coefficients were computed. Skipped rxy values were replaced using 
cubic spline interpolation. The second method involved parallelizing a portion of the 
template matching code for multi-core processor environments and implemented on a 
laptop (Intel Core Duo T2300 @ 1.66 GHz, 2 GB DDR2). The third method combined 
both the skip indexing and parallelized methods. Skipping samples, parallelizing code, 
and a combination of the two methods reduced computation time (17.2 s original) by 
approximately 64% (6.2 s), 58% (7.3 s), and 82% (3.16 s) respectively. These data are 
based on the results of 3 simulations of each technique using an ECG segment of 600,000 
samples and a template of 161 samples in length. 
If the correlation between template and ECG segment exceeded a defined threshold 
value a detection flag was set to high. This flag was held in a high state until rxy dropped 
below a defined lower threshold (see Fig. 14). High and low thresholds were set to 0.35 
and 0.4 respectively and were determined by personal judgment based on trial and error 
testing. A QRS complex was set as the largest rxy peak between any high and low 
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detection flag switches. This double threshold method helps eliminate multiple peak 





Fig. 14 – QRS detection using template matching. Plots include (a) example template 
used for QRS detection by template matching, (b) rat ECG with detected QRS 
complexes, (c) rxy data series and peaks detected using the double threshold technique, 
and (d) state of the detection flag used in the double threshold technique. 
 
5.2.5 HRV Analysis 
Twenty-seven HRV measures were used based on the recommended procedures in 
the literature. Time-domain HRV measures considered included mean IBI, mean HR, 
pNN10, SDNN, SDNNi, HRVti, and TINN. LF and HF power in absolute and 
normalized units were considered for both frequency-domain and time-frequency 
analysis. To quantify sympatho-vagal balance LFHF was considered using both 
frequency-domain and time-frequency analysis. Similarly, the global sympatho-vagal 
equilibrium was computed using the rLFHF measure. Finally, nonlinear HRV analysis 





Table 5 – HRVAS Analysis Options for Hyperaldosteronism Datasets 
Analysis Parameter (value) or Method 
Ectopic Detection Std. Dev. (3), percent (20%) 
Ectopic Correction Remove ectopic 
Detrending Smoothness Priors (155) 
Time-Domain pNNx (10 ms), SDNNi (0.5 min), HRVti and TINN (32 bins) 
Freq.-Domain VLF (0-0.16 Hz), LF (0.16-0.6 Hz), HF (0.6-3 Hz), 
Interpolation Rate (10 Hz), Points in PSD (512 pts)  
Nonlinear SampEn (r=0.5 std, m=2) [133], DFA (n=4 to 64, Break Point 
=10) 
Time-Freq. Window (30 s), Overlap (15 s) 
 
5.2.6 Statistical Analysis 
In order to check the previously stated hypotheses, several statistical techniques were 
used. Descriptive statistics were firstly provided for each variable concerning the HRV 
for both control and treated groups. As the factors in this study are time and treatment, a 
two-factor repeated measures ANOVA was used to test the main effects of each factor on 
HRV measures in addition to possible interaction effects. The assumption of sphericity 
was checked by Mauchly’s test of sphericity. When the sphericity assumption was 
violated, epsilon measures were compared to the value 0.75. If epsilon values were under 
the level of 0.75, the Greenhouse-Geisser method was used to compute the F statistic. 
Otherwise F statistic was computed by the Huynh-Feldt method. Post hoc tests were also 
performed when the main effects were significant. For the case of significance of 
interaction, a one-factor, repeated measure ANOVA was done. In this special case, the p-
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values are compared with the value 0.05 divided by 2 or 0.025. Statistical analysis was 
performed using SPSS v16 (SPSS, Chicago, IL). 
5.3 Results 
Results of HRV analysis are summarized in Table 6. The following statistics are 
presented as mean ± standard deviation for control vs. ALDOST respectively. ANOVA 
results indicated significant differences in the treatment factor between the control and 
ALDOST group for mean HR (298.9±12.3 vs. 324.4±35.3). The main effect of time was 
found to be significantly different for the following HRV measures: mean IBI (187.6 
±22.4 vs. 202.0 ±15.3), mean HR (298.9 ±21.7 vs. 324.4 ±35.3), RMSSD (3.2 ±1.3 vs. 
3.7 ±1.7), SDNN (2.3 ±0.9 vs. 2.6 ±1.1), and SD1 (2.3 ±0.9 vs. 2.6 ±1.2). Similarly, there 
were significant interactions (time*treatment) found for mean IBI, mean HR and 
RMSSD. 
Mean IBI, mean HR, and RMSSD were further analyzed by one-factor repeated 
measures ANOVA because of significant interaction between time and treatment. The 
effect of time was significant (α=0.025) on mean IBI in both controls (p=0.002) and 
ALDOST (p=0.001) groups. The effect of time was also significant on mean HR in both 
controls (p=0.002) and ALDOST (p=0.006) groups. Finally, the effect of time was not 
significant on RMSSD in controls (p=0.146) but was significant in ALDOST (p=0.005). 
68 
 
Table 6 – HRV Anaylsis Results for Hyperaldosteronism Datasets 
p-
between
Measure (units) Time Time*Treat Treatment Mean ± SD Mean ± SD
MeanIBI (ms) *** *** ns 202.02 ± 15.28 187.62 ± 22.39
MeanHR (bpm) *** *** * 298.91 ± 21.72 324.35 ± 35.31
pNN10 (%) ns ns ns 1.38 ± 2.80 2.39 ± 4.95
RMSSD (ms) * ** ns 3.18 ± 1.25 3.70 ± 1.72
SDNN (ms) * ns ns 2.31 ± 0.93 2.58 ± 1.14
SDANN (ms) ns ns ns 2.17 ± 0.86 2.44 ± 1.04
HRVti ns ns ns 7.72 ± 2.97 7.32 ± 2.38
TINN (ms) ns ns ns 6.30 ± 2.95 6.34 ± 2.90
aLF (ms
2
) ns ns ns 0.03 ± 0.03 0.02 ± 0.02
aHF (ms
2
) ns ns ns 0.15 ± 0.07 0.13 ± 0.06
aTotal (ms
2
) ns ns ns 0.19 ± 0.09 0.16 ± 0.07
nLF (n.u.) ns ns ns 0.17 ± 0.10 0.14 ± 0.07
nHF (n.u.) ns ns ns 0.83 ± 0.10 0.86 ± 0.07
LFHF (ratio) ns ns ns 0.23 ± 0.18 0.18 ± 0.12
aLF (ms
2
) ns ns ns 2.52 ± 2.83 2.74 ± 3.07
aHF (ms
2
) ns ns ns 10.53 ± 8.90 14.95 ± 15.44
aTotal (ms
2
) ns ns ns 13.85 ± 11.94 18.50 ± 18.89
nLF (n.u.) ns ns ns 0.18 ± 0.10 0.15 ± 0.06
nHF (n.u.) ns ns ns 0.82 ± 0.10 0.85 ± 0.06
LFHF (ratio) ns ns ns 0.24 ± 0.17 0.19 ± 0.09
rLFHF ratio) ns ns ns 0.03 ± 0.08 0.01 ± 0.01
SD1 (ms) ** ns ns 2.26 ± 0.88 2.62 ± 1.22
SD2 (ms) ns ns ns 8.02 ± 3.28 9.61 ± 3.21
SampEn ns ns ns 1.89 ± 0.45 1.76 ± 0.44
DFA-α1 ns ns ns 0.68 ± 0.20 0.64 ± 0.16
DFA-α2 ns ns ns 1.35 ± 0.16 1.39 ± 0.12
ns = not significant,  * = p<0.05,  ** = p<0.01,  *** = p<0.005













The majority of HRV measures showed no significant differences between treatment 
groups, effect of time, or their interaction. The five measures (mean IBI, mean HR, 
RMSSD, SDNN, and SD1) that did show significance could be questioned because of 
overlapping standard deviations, abrupt shifts in measured variability,  (see Appendix B) 
and/or consideration of study limitations. First, the mean value of all five significant 
HRV measures obtained at week eight of aldosterone treatment has a relatively large 
deviation from the previous weeks (see Appendix B). Mean IBI, SDNN, RMSSD, and 
SD1 abruptly deflects to higher values while mean HR deflects to lower values. For mean 
IBI and mean HR this deviation could be explained if an exponential response to 
treatment was expected. Also, an increasing and decreasing linear time response to 
control treatments can be observed in both mean IBI and mean HR measures respectively 
(see Appendix B). However, control conditions were expected to produce no significant 
changes with respect to time. 
Other factors and limitations are likely responsible for the unexpected significances in 
HRV. The foremost limitation to consider was the small sample size. Another limitation 
was the method used for choosing a single 10-minute IBI interval from 7 hours of ECG 
data. As discussed before, segments were chosen based on HR and ectopic interval 
criteria. The segment of lowest HR was assumed to be the segment of least movement 
and was chosen to keep the level of activity between subjects as constant as possible. 
This was a suggestion made by other HRV authors [134]. Ideally all ECG would be 
recorded during controlled and repeatable environmental and physiological conditions, 
but the available data were from previous work. Alternatively, one could segment ECG 
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using activity levels or EEG sleep stages as discussed below. Again, neither of these 
parameters was available.  
Another limitation that may have contributed to the unexpected significances was the 
inability to control for effects of sleep stages on HRV. Others have shown that, in 
humans, the sleep stage determined via EEG can affect HRV [135-139]. Because no EEG 
data were present, a possible solution could be to perform HRV analysis on 12 or 24 
hours of IBI in an effort to average out any effect of sleep cycles. Using such long data 
series increase the probability of non-stationarities. However, time-frequency and certain 
nonlinear HRV analysis methods obviate non-stationarities. During this stage of the 
study, the computing resources to perform HRV analysis on 12 or 24 hours of rat IBI data 
were not available. 
Physiological changes seen from a rat hyperaldosteronism model are possibly not 
significant enough to elucidate the reduction of HRV seen in complete CHF of humans. 
If HRV changes exist in CHF populations but not in the hyperaldosteronism rat model, 
then the HRV changes seen in human CHF may be primarily due to neural related 
changes and not cardiac remodeling. The hyperaldosteronism studies consider 
cardiovascular changes and little if any neural change. As noted in Chapter 1.2 
cardiovascular performance and neural control are closely interlinked. 
There also exists the possibility that “variability” is altered in the presented model but 
not detectable using the current methods. Let us assume that physiological changes do 
exist in the rat hyperaldosteronism model and that these changes do affect variability 
within the heart firing sequences. Perhaps the changes in variability, calculated using the 
current methods, are lost due to condensing of all cardiac events into a single time point 
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(the R-wave). Any changes in sub-beat variability such as the PR, QRS, or QT interval 
may be lost by only considering RR interval variability.  
Finally, as with most animal models of human pathophysiology, there can be 
concerns of comparing two different species and whether the model is representative. 
Some authors consider the physiological origins or meanings of HRV in rats to be similar 
to that in humans [67] but with varying working parameters. For instance, the oscillations 
seen in spectral based HRV measures, e.g. RSA and Mayer, are present in both rat and 
human but centered at differing frequencies. No one has yet to verify the significance of 
most HRV measures, particularly nonlinear measures, between species. 
5.5 Conclusion 
The rat hyperaldosteronism model of HF in the study was generally unable to 
reproduce the changes in HRV expected based on other HF studies. Given that 
improvements are made to the protocol and/or more research is done to improve the 
understanding of HRV in rats compared to humans, the model could prove useful in 




6 Summary and Conclusions 
HRVAS provides researchers an easy to use graphical user interface, several formats 
for importing data, batch processing, and tools for exporting. Analysis features of 
HRVAS include IBI preprocessing, time-domain, frequency-domain, time-frequency, and 
nonlinear HRV analysis. Researchers also have the ability to completely customize the 
source code to suit their personal preferences or study needs. These usability and analysis 
features are all useful in studying HRV. 
Software evaluations of HRVAS using simulated data and public CHF data helped to 
demonstrate its accuracy and worth as a HRV analysis tool. Application of HRVAS to 
study HRV in rat hyperaldosteronism models further displayed value of its use as a viable 
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Appendix A – HRVAS Analysis Modules 
 





Fig. 16 – Time-domain Analysis Module 
 
 





Fig. 18 – Poincaré Analysis Module 
 
 









Appendix B – Additional Statistics 
 
Table 7 – Test of Within-Subjects Contrast for mean IBI 
Treatment Fit Sig 
Control Linear 0.001 
 Quadratic 0.694 
 Cubic 0.457 
 Order 4 0.079 
Aldost Linear 0.000 
 Quadratic 0.008 
 Cubic 0.059 
 Order 4 0.018 
 
 
Table 8 – Tests of Within-Subjects Contrast for mean HR 
Treatment Fit Sig 
Control Linear 0.000 
 Quadratic 0.670 
 Cubic 0.476 
 Order 4 0.066 
Aldost Linear 0.001 
 Quadratic 0.018 
 Cubic 0.086 





Table 9 – Tests of Within-Subjects Contrast for RMSSD 
Treatment Fit Sig 
Control Linear 0.076 
 Quadratic 0.208 
 Cubic 0.517 
 Order 4 0.666 
Aldost Linear 0.372 
 Quadratic 0.049 
 Cubic 0.023 
 Order 4 0.129 
 
 
Table 10 – Tests of Within-Subjects Contrast for SDNN 
Treatment Fit Sig 
Control Linear 0.062 
 Quadratic 0.235 
 Cubic 0.657 
 Order 4 0.677 
Aldost Linear 0.397 
 Quadratic 0.062 
 Cubic 0.019 




Table 11 – Tests of Within-Subjects Contrast for SD1 
Treatment Fit Sig 
Control Linear 0.082 
 Quadratic 0.185 
 Cubic 0.512 
 Order 4 0.687 
Aldost Linear 0.392 
 Quadratic 0.048 
 Cubic 0.021 










Fig. 22 – Distribution of mean HR by treatment time and treatments group 
 
 









Fig. 25 – Distribution of SD1 by treatment time and treatments group 
